Skip to main content
Clinical Trials/JPRN-jRCTs031210673
JPRN-jRCTs031210673
Recruiting
Phase 3

Ramelteon for prevention of postoperative delirium in delirium high-risk cancer patients.: A randomized, double-blind, placebo-controlled multi-center trial, JORTC-PON02/J-SUPPORT2103/NCCH2103. - RAMP trial

Matsuoka Hiromichi0 sites766 target enrollmentApril 1, 2022

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Delirium
Sponsor
Matsuoka Hiromichi
Enrollment
766
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 1, 2022
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Matsuoka Hiromichi

Eligibility Criteria

Inclusion Criteria

  • 1\) Pathologically confirmed and/or clinically suspected malignant tumor
  • 2\) Aged 65 or older at enrollment
  • 3\) Undergoing surgery under general anesthesia and postoperative hospitalization for 5 days or over
  • 4\) Preoperative ability to take medication orally or via nasogastric tube and postoperative plan to take medication orally or via nausal gastric tube from postoperative day 2 or earlier.
  • 5\) Written informed consent from patient or written informed consent from witness, who is not working in the present study, with patient's oral consent.

Exclusion Criteria

  • 1\) Diagnosed as delirium with DSM\-5 at enrollment
  • 2\) Allergy to ramelteon
  • 3\) Sevea liver dysfunction according to criteria of total bil \> 2\.25 mg/dL, AST \> 90 U/L, ALT \> 126 U/L for male, or ALT \> 69 U/L for female
  • 4\) History of participation to clinical trials within 4 weeks including a day of enrollment except for the completed protocol treatment and in the observation period
  • 5\) History of medication of ramelteon or flurvoxamine within 2 weeks including a day of enrollment
  • 6\) History of medication of suvorexant or lemborexant 2 weeks including a day of enrollment
  • 7\) History of epilepsy, Parkinson's dosease, or dementia with lewy bodies
  • 8\) Lactose intolerance
  • 9\) Planned surgical procesure including central nervous system or intracranial region.
  • 10\) History of drug or alcohol use disorder or daily alcohol intake over 60g or alcohol\-related disease within 5 years including a day of enrollment

Outcomes

Primary Outcomes

Not specified

Similar Trials